James F. Donohue, MD
Professor of Medicine
Chief, Division of Pulmonary and Critical Care Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Ketan Sheth, MD, MBA
Lafayette Allergy & Asthma Clinic
Interviewer: Seymour I. Schlager, MD, PhD
Physicians, PAs: 2
Nurses, NPs: 2.4 (50 minute hour) Medium
Obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are leading causes of morbidity and mortality in the United States. The incidence of asthma has nearly doubled in the last 20 years and the disease now affects more than 20 million Americans. Similarly, at least 20 million Americans suffer from COPD, a condition that is significantly under-diagnosed and under-treated. Each year, asthma and COPD account for nearly 4 million emergency department visits. In addition, COPD has now become the fourth leading cause of death in the US, and is expected to jump to third by the year 2020.
Despite the fact that asthma and COPD frequently share overlapping characteristics in presentation, each of these conditions has a different pathogenesis, prognosis, treatment, and set of accepted pharmacotherapy guidelines. Thus, making an early and accurate differential diagnosis is essential to optimal patient management.
The monograph portion of this activity is intended to provide an overview of these two important obstructive respiratory diseases with the goal of providing practical information for the management of patients with COPD and asthma in the primary care setting. In addition, the audio presentation will provide “clinical pearls” from two experts in the field--one specializing in the management of COPD and one in asthma—regarding the optimal approach to the patient with obstructive lung disease.
. Target Audience
This educational activity is designed to meet the needs of primary care physicians, nurses, nurse practitioners, and physician assistants with an interest in the epidemiology, diagnosis, and management of chronic obstructive pulmonary disease or asthma.
Upon completion of this educational activity, the participant should be able to:
Describe the pathophysiology of COPD and asthma, and the unique pathogenic characteristics of each condition
Discuss the early diagnosis of COPD, the staging of disease severity, and the use of FEV
1 reduction as a prognostic indicator Describe the latest pharmacological therapy for mild, moderate, and severe COPD and asthma
Discuss the optimal smoking cessation approaches that primary care providers can adopt for the prevention of COPD in their patients
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
James F. Donohue, MD discloses that he has received compensation as a member of speakers’ bureaus and advisory boards for GlaxoSmithKline.
Ketan K. Sheth, MD, MBA discloses that he has received compensation as a member of speakers’ bureaus for AstraZeneca, GlaxoSmithKline, Pfizer Inc, sanofi-aventis, and Schering-Plough; for product consultation for Altana Inc., and GlaxoSmithKline, and as a member of advisory committees for Altana Inc., and GlaxoSmithKline. He also is a shareholder in Merck & Co., Inc.
Seymour I. Schlager MD PhD discloses that he has received compensation as a product consultant for Abbott Laboratories and is a share holder of Abbott Laboratories and Pfizer Inc.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their
participation in the activity.
Release Date: May 28, 2006 Credit Expiration Date: May 28, 2008
This program has been reviewed and is approved for a maximum of 2 hours of AAPA Category I (Preapproved) CME credit by the Physician Assistant Review Panel of the American Academy of Physician Assistants. Approval is valid for one year from the issue date of May 28, 2006. Participants may submit the self-assessment at any time during that period.
This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
AKH Inc. designates this educational activity for 2.4 contact hours. (based on 50 minute hour)
AKH Inc. is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. Provider #030803. AKH Inc. designates this educational activity for 2.4 contact hour(s). (based on 50 minute hour)
It should take approximately 120 minutes to listen to the audio presentation, read the monograph PDF and complete the self-assessment. Successful completion of the self-assessment, defined as a cumulative score of at least 70% correct, is required to earn credit. Commercial Support Statements
Supported through an educational grant from GlaxoSmithKline.
This program consists of an MP3 audio file and PDF monograph. You will need a current Flash player and Adobe Acrobat Reader to complete the program. The audio portion will require approximately 60 minutes to complete. Reading the monograph and completing the post-test will require an additional 60 minutes.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Save the PDF file to your computer or open the file using the Adobe Acrobat Reader. Print a copy of the monograph, which includes the post-test and program evaluation.
Read the monograph in its entirety.
Play the audio file by clicking on the play button.
After reading the monograph and listening to the audio, complete the post-test and evaluation found on the last two pages of the monograph. Mail the pages according to printed instructions. A certificate of credit for satisfactory completion (70% or better) will be mailed within 4 to 6 weeks.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this publication and audio CD are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or GlaxoSmithKline. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients' conditions and of possible contraindications or risks, and without a review of any applicable manufacturer's product information and comparison with the recommendations of other authorities.